Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 135 citing articles:

Type 2 diabetes
Ehtasham Ahmad, Soo Lim, Roberta Lamptey, et al.
The Lancet (2022) Vol. 400, Iss. 10365, pp. 1803-1820
Closed Access | Times Cited: 541
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Juan P. Frías, Srikanth Deenadayalan, Lars Erichsen, et al.
The Lancet (2023) Vol. 402, Iss. 10403, pp. 720-730
Closed Access | Times Cited: 144
What is the pipeline for future medications for obesity?
Eka Melson, Uzma Ashraf, Dimitris Papamargaritis, et al.
International Journal of Obesity (2024)
Open Access | Times Cited: 103
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Ania M. Jastreboff, Robert F. Kushner
Annual Review of Medicine (2023) Vol. 74, Iss. 1, pp. 125-139
Open Access | Times Cited: 78
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Daniel J. Drucker
Diabetes Care (2024)
Open Access | Times Cited: 72
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Julian M. Yabut, Daniel J. Drucker
Endocrine Reviews (2022) Vol. 44, Iss. 1, pp. 14-32
Open Access | Times Cited: 70
Forensic and Pharmaceutical Risks in the Organization of Pharmacotherapy of Covid, Post-Covid and Long-Covid Disorders. COVID-19 and Vaccination Practice Standards.
Вікторія Шаповалова
SSP Modern Pharmacy and Medicine (2022) Vol. 2, Iss. 4, pp. 1-24
Open Access | Times Cited: 70
An update on peptide-based therapies for type 2 diabetes and obesity
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2023) Vol. 161, pp. 170939-170939
Open Access | Times Cited: 70
Derivatization with fatty acids in peptide and protein drug discovery
Peter Kurtzhals, Søren Østergaard, Erica Nishimura, et al.
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 1, pp. 59-80
Closed Access | Times Cited: 69
Obesity-related kidney disease: Beyond hypertension and insulin-resistance
Tarek Ziad Arabi, Areez Shafqat, Belal Nedal Sabbah, et al.
Frontiers in Endocrinology (2023) Vol. 13
Open Access | Times Cited: 45
Targeting the incretin system in obesity and type 2 diabetes mellitus
Saleem Ansari, Bernard Khoo, Tricia Tan
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 8, pp. 447-459
Closed Access | Times Cited: 29
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Jens J. Holst
Nature Metabolism (2024) Vol. 6, Iss. 10, pp. 1866-1885
Open Access | Times Cited: 18
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review
Nasreen Alfaris, Stephanie W. Waldrop, Veronica Johnson, et al.
EClinicalMedicine (2024) Vol. 75, pp. 102782-102782
Open Access | Times Cited: 16
Updates on Methods for Body Composition Analysis: Implications for Clinical Practice
Diana M. Thomas, Ira Crofford, J. D. Scudder, et al.
Current Obesity Reports (2025) Vol. 14, Iss. 1
Closed Access | Times Cited: 2
Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control
Paul El Meouchy, Mohamad Wahoud, Sabine Allam, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12305-12305
Open Access | Times Cited: 64
New therapies for obesity
Dimitris Papamargaritis, Carel W. le Roux, Jens J. Holst, et al.
Cardiovascular Research (2022) Vol. 119, Iss. 18, pp. 2825-2842
Open Access | Times Cited: 41
Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options
Angelica Artasensi, Angelica Mazzolari, Alessandro Pedretti, et al.
Molecules (2023) Vol. 28, Iss. 7, pp. 3094-3094
Open Access | Times Cited: 35
Current and future pharmacotherapies for obesity in children and adolescents
Aaron S. Kelly
Nature Reviews Endocrinology (2023) Vol. 19, Iss. 9, pp. 534-541
Closed Access | Times Cited: 28
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Christine R. Andreasen, Andreas Andersen, Tina Vilsbøll
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1846-1858
Open Access | Times Cited: 26
Pharmacological Support for the Treatment of Obesity—Present and Future
Marcin Kosmalski, Kacper Deska, Bartłomiej Bąk, et al.
Healthcare (2023) Vol. 11, Iss. 3, pp. 433-433
Open Access | Times Cited: 24
Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity
Stjepan Eržen, Gašper Tonin, Dubravka Jurišić‐Eržen, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1517-1517
Open Access | Times Cited: 13
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2024) Vol. 173, pp. 171149-171149
Open Access | Times Cited: 11
Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?
Elena Domingo, Patrice Marqués, Vera Francisco, et al.
Pharmacological Research (2024) Vol. 200, pp. 107058-107058
Open Access | Times Cited: 11
Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis
Hong Li, Guanzheng Yu, Huang Qi, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116150-116150
Open Access | Times Cited: 10
New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists
Ferenc Sztanek, László Imre Tóth, Attila Pető, et al.
Biomedicines (2024) Vol. 12, Iss. 6, pp. 1320-1320
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top